Theriva Biologics, Inc.
TOVX · XNYSCIK 894158fmd_18MNB39EXBWCV079HW8X41QYMTManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
Latest annual · FY2025
Millions- Operating income
- (24)
- Net income
- (24)
- Free cash flow
- (17)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Operating income
- (2)
- Net income
- (1)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Theriva Biologics, Inc. (TOVX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$24.1 million | -$26.3 million | 10-K 2026-03-12 · proof | |
| Net income | -$23.7 million | -$25.7 million | 10-K 2026-03-12 · proof | |
| Cash from operating activities | -$16.7 million | -$16.9 million | 10-K 2026-03-12 · proof | |
| Free cash flow | -$16.7 million | -$16.9 million | 10-K 2026-03-12 · proof | |
| Total assets | $38.2 million | $35.4 million | +8.2% | 10-K 2026-03-12 · proof |
| Total liabilities | $22.9 million | $16.3 million | +40.4% | 10-K 2026-03-12 · proof |
| Cash and cash equivalents | $13.1 million | $11.6 million | +12.5% | 10-K 2026-03-12 · proof |
- What was Theriva Biologics, Inc. (TOVX)'s operating income in fiscal 2025?
- Theriva Biologics, Inc. (TOVX) reported operating income of -$24.1 million for fiscal 2025 (the year ended Dec 31, 2025), against -$26.3 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Theriva Biologics, Inc. (TOVX)'s net income in fiscal 2025?
- Theriva Biologics, Inc. (TOVX) reported net income of -$23.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$25.7 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Theriva Biologics, Inc. (TOVX)'s cash from operating activities in fiscal 2025?
- Theriva Biologics, Inc. (TOVX) reported cash from operating activities of -$16.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$16.9 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What was Theriva Biologics, Inc. (TOVX)'s free cash flow in fiscal 2025?
- Theriva Biologics, Inc. (TOVX) reported free cash flow of -$16.7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$16.9 million the year before. Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Theriva Biologics, Inc. (TOVX)'s total assets?
- As of Dec 31, 2025, Theriva Biologics, Inc. (TOVX) reported total assets of $38.2 million, against $35.4 million a year earlier (+8.2%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Theriva Biologics, Inc. (TOVX)'s total liabilities?
- As of Dec 31, 2025, Theriva Biologics, Inc. (TOVX) reported total liabilities of $22.9 million, against $16.3 million a year earlier (+40.4%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
- What are Theriva Biologics, Inc. (TOVX)'s cash and cash equivalents?
- As of Dec 31, 2025, Theriva Biologics, Inc. (TOVX) reported cash and cash equivalents of $13.1 million, against $11.6 million a year earlier (+12.5%). Source: the 10-K filed with the SEC on Mar 12, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:TOVX&period_type=annual&limit=5"Information only, not investment advice.